Trending Stocks, Investing Tips, and Market Insights on Stockchase

This pharma company is a major holding within XLV, but worth owning itself. The company just reported Q2 earnings, with total net revenues beating, bolstered by 10.2% sales growth. To replace its blockbuster drug, Humira, AbbVie launched Skyrizi which boasts global sales of $5.5 billion, and Rinvoq (global sales of over $2.5 billion). AbbVie's overall sales growth was 10.2%.